T1 Matrix metalloproteinase-driven tissue destruction in Human Tuberculosis (TB) is mediated by Th-17 cytokines and the PI3K/p110a/p70S6K cascade
T2 Single nucleotide polymorphisms in the ficolin-2 gene predispose to Pseudomonas aeruginosa infection and disease severity in non-cystic fibrosis bronchiectasis
T3 Measuring eosinophil kinetics in humanS
T4 Safety and expression of a single dose of lipid-mediated CFTR gene therapy to the upper and lower airways of patients with Cystic Fibrosis
T5 The KCa3.1 K+ channel mediates wound healing in human myofibroblasts
T6 TRAIL is a potential novel therapeutic target in pulmonary arterial hypertension
S1 Evidence-based case definition for EAA due to metalworking fluid exposure
S2 Occupational exposure, breathlessness and COPD in a general population of older UK men
S3 Work performance and airflow obstruction in a general UK population of older workers
S4 Occupational asthma; is this the cause of excess respiratory symptoms and COPD described in bitumen exposed workers?
S5 The prevalence of asthma among cleaners in the UK
S6 Supermarket bakers asthma
S7 Adiposity and asthma, pulmonary function and atopy in 11-year old children
S8 Sensitivity of impulse oscillometry and spirometry in the assessment of beta-blocker induced bronchoconstriction and beta-agonist bronchodilatation in mild-to-moderate asthmatics
S9 Inhaled and systemic corticosteroid response in moderate-to-severe asthma assessed by extended exhaled nitric oxide and lung function
S10 Is a high FeNO a marker of non-adherence in difficult asthma?
S11 Inappropriate prescribing of combination inhalers in asthma in Northern Ireland (NI)
S12 Unscheduled healthcare resource utilisation and health-related quality of life before and after omalizumab initiation in UK clinical practice
S13 Differentiated human rhinovirus loads in stable COPD and at exacerbation
S14 Histone deacetylase activity is reduced in COPD subjects during rhinovirus induced exacerbations
S15 Detection of bacteria in sputum following experimental rhinovirus infection is more common in COPD than controls subjects
S16 Molecular profiling of the airway microbiome in COPD
S17 Impact of COPD severity and sputum production on antibiotic resistance
S18 A comparison of prevalence and load of airway bacteria in COPD patients with paired stable and exacerbation state samples
S19 Molecular fingerprinting and metagenomic analysis reveals a polymicrobial element in patients with chronic obstructive pulmonary disease
S20 Time-resolved CT pulmonary angiography contrast transit time in patients with pulmonary embolism
S21 Objective and patient reported outcomes of long term management of patients with chronic thromboembolic pulmonary hypertension (CTEPH)
S22 Improved symptoms and quality of life after pulmonary endarterectomy (PEA) in patients with chronic thromboembolic disease (CTED) and borderline pulmonary hypertension (PH)
S23 Accuracy of contrast enhanced MR lung perfusion compared to perfusion scintigraphy in diagnosing chronic thromboembolic pulmonary hypertension
S24 Incidence of persistent perfusion defects following pulmonary embolism
S25 Incidence of surgically treated patients with chronic thromboembolic pulmonary hypertension in the UK during the last decade
S26 Barriers to attendance and adherence at pulmonary rehabilitation
S27 MRC grade 2
S28 Is a pulmonary rehabilitation programme for patients undergoing curative lung cancer surgery feasible?
S29 Assessing the educational impact of pulmonary rehabilitation in non-COPD patients using the lung information needs questionnaire
S30 An evaluation of the systemic inflammatory response to endurance walking in patients with COPD
S31 Energy expenditure and physical activity levels during an 8-week pulmonary rehabilitation programme
S32 Loss/inhibition of the aVb5 integrin reduces allergen-induced increases in airway smooth muscle mass in in vivo models of asthma
S33 Vitamin D and airway remodelling in paediatric severe therapy resistant asthma
S34 The adhesion receptor CADM1 on mast cells mediates adhesion to lung fibroblasts and smooth muscle
S35 Rapamycin inhibits IL-33-induced, nuocyte-driven airway inflammation
S36 The adhesion receptor CADM1 promotes human mast cell viability
S37 Myd88 deficiency influences murine tracheal epithelial metaplasia and submucosal gland abundance
S38 Community-based evaluation of immigrant TB screening using interferon Gamma release assays and tuberculin skin testing
S39 Migration and tuberculosis
S40 A cross sectional investigation to determine the background prevalence of latent tuberculosis infection in unselected medical inpatients in a low prevalence region of UK reveals high rates of IGRA positivity
S41 Screening for latent TB in HIV
S42 Early Identification of Mycobacterium tuberculosis (M.tb) and Mycobacterium other than tuberculosis (MOTT) by “cord formation” evaluation in liquid culture
S43 Polyfunctional T cells reveal the spectrum of tuberculosis in HIV co-infection through the identification of immunological correlates of latent and active disease
S44 Lung clearance index (LCI) and FEV1 correlate equally with treatment burden as measured by cystic fibrosis questionnaire-revised (CFQ-R)
S45 Clinical efficacy of seasonal influenza vaccination in adults with cystic fibrosis
S46 A comparison of three different specimen types for the diagnosis of viral respiratory infections in adults with cystic fibrosis
S47 Pseudomonas aeruginosa induces apoptosis in human dendritic cells
S48 Mucoidy and the microbiome
S49 Increased skeletal muscle-specific microRNA-1 in the blood of COPD patients
S50 Nitrative stress is increased in COPD exacerbations following experimental rhinovirus infection
S51 Reducing intracellular aggregation and improving the secretion of Z alpha-1 antitrypsin
S52 Association of microtubule instability with defective phagocytosis in COPD
S53 Alarmins in bronchiolitis obliterans syndrome after lung transplantation
S54 Polymers of Z α1-antitrypsin are associated with pulmonary infection post lung transplantation
S55 Cost-effectiveness and quality of life results from the ASTER study
S56 EBUS-TBNA prevents mediastinoscopies in patients with isolated mediastinal lymphadenopathy
S57 Gene expression profiling of endobronchial ultrasound-derived cytological aspirates from hilar and mediastinal lymph nodes in NSCLC
S58 Beta-Catenin determines tracheal cell fate and squamous lung cancer progression by modulating intercellular adhesiveness
S59 Chemo-immunotherapy of mesothelioma
S60 Mesenchymal stem cells expressing TRAIL induce apoptosis in malignant pleural mesothelioma
S61 RAPID score
S62 Appearances of empyema on CT
S63 Telehealth in acute community acquired pneumonia
S64 Understanding better the pathophysiology of aspiration pneumonia
S65 Early supported discharge scheme (ESDS) for pneumonia & lower respiratory tract infection (LRTI)
S66 Is hospital readmission an appropriate outcome measure for community-acquired pneumonia?
S67 Characterisation of the endothelial outgrowth cell
S68 Inhibition of p38 mitogen activated protein kinase (MAPK) prevents the development of experimental pulmonary hypertension
S69 Serum osteoprotegerin predicts mortality in a prospective study on incident cases of pulmonary arterial hypertension
S70 Diagnostic utility and prognostic value of quantitative cardiac MR indices in patients with suspected pulmonary hypertension
S71 Influence of age on clinical phenotypes of incident idiopathic pulmonary arterial hypertension. Results from the pulmonary hypertension registry of the UK and Ireland
S72 Prediction of survival in pulmonary arterial hypertension using survival equations. Results from the pulmonary hypertension registry of the UK and Ireland
S73 Macrophages as vehicles for delivering cell therapy to injured lung
S74 Increased plasma levels of syndecan-1 and sFlt-1 during cardiopulmonary bypass surgery
S75 Do “clinically relevant” tidal volumes really cause ventilator-induced lung injury in mice?
S76 Proteinase 3 activity in sputum from alpha-1-antitrypsin deficient subjects
S77 Comparing the degree of inhibition of TNF-α and IL-6 by p38 inhibitors in monocyte derived macrophages (MDMs)
S78 Differentiation of monocytes to pro-inflammatory forms is influenced by cigarette smoke and HLA type in COPD
S79 Specific functional antibody deficiency is associated with a reduction lung function in the severe asthma population
S80 Localisation of the site of fixed airflow obstruction in moderate to severe asthma using hyperpolarised helium-3 MRI
S81 Refractory asthma in the UK
S82 Fungal sensitisation in children with severe therapy resistant asthma
S83 Repeatability and inter-relationships of small airway biomarkers
S84 Can clinicians accurately predict non-adherence to medication in patients with difficult asthma? A comparison between clinical judgement and prescription issue data
S85 British Thoracic Oncology Group Trial, BTOG2
S86 Quality of life in advanced non-small cell lung cancer, effects of cisplatin dose and carboplatin in combination with gemcitabine
S87 Delivered dose intensity of gemcitabine 1250 mg/m2 with cisplatin at 80 mg/m2 (GC80) and 50 mg/m2 (GC50) and carboplatin AUC 6 (GCb6) in a phase III trial of advanced non-small cell lung cancer (NSCLC)
S88 Day case cisplatin delivery for advanced NSCLC patients
S89 A meta-analysis of limited resection vs lobectomy for stage I non-small cell lung cancer
S90 Nurse specialist input is independently associated with anti-cancer treatment in lung cancer
S91 Aspergillus fumigatus sensitisation in patients with chronic obstructive pulmonary disease
S92 Cognitive function & cerebral white matter tract microstructure in COPD
S93 The development of a novel scale to screen and measure anxiety in patients with chronic obstructive pulmonary disease (COPD)
S94 Ultrasound measurement of quadriceps wasting in early chronic obstructive pulmonary disease and its relationship with daily physical activity
S95 Effect of pulmonary rehabilitation on cardiovascular risk factors in COPD
S96 Survival after the first myocardial infarction is shorter in patients with COPD compared to the general population
S97 BMPR2 R899X knock-in mice developed age-related pulmonary hypertension
S98 BMPR-II mutations do not predispose to pulmonary arterial hypertension in a mouse model of schistosomiasis
S99 The anti-malarial drug and lysosomal inhibitor, chloroquine, increases cell surface expression of BMPR-II
S100 The bone morphogenetic protein type II receptor is critical for venous angiogenesis in zebrafish
S101 Heterozygous loss of BMPR-II predisposes to inflammatory cytokine secretion and pulmonary vascular smooth muscle proliferation
S102 The crosstalk of PDE inhibitor with BMP signalling pathway in human pulmonary arterial smooth muscle cells
S103 Microbial community composition in the lungs of patients with Cystic Fibrosis and non-CF bronchiectasis
S104 The culture microbiome in the lungs of patients with COPD
S105 Longitudinal microbiology of adult non-CF bronchiectasis
S106 A randomised double blind 13 week crossover trial of hypertonic saline (HTS) (6%) vs isotonic saline (ITS) (0.9%) in patients with bronchiectasis
S107 The influence of viral symptoms in infective exacerbations of non-cystic fibrosis bronchiectasis
S108 Expert consensus on diagnostic criteria and tertiary service requirements for bronchiectasis
S109 Contribution of aberrant monocyte-natural killer T (NKT) cell axis to immune-pathology in sarcoidosis
S110 Targeted deletion of Gαq/Gα11 in surfactant protein C-positive epithelial cells reduces TGFß activation and results in inflammation and alveolar airspace enlargement
S111 The role of TNF-related apoptosis inducing ligand (TRAIL) in pulmonary fibrosis
S112 TNF-R1 Ubiquitous Scaffolding and Signalling protein (TRUSS) is a regulator of TNF-α induced NF-κ-B activation
S113 The influenza virus activates TGFß via an αVß6-integrin mediated pathway
S114 Lymphatic vessel distribution in fibrotic lung diseases
S115 The effect of posture on the 2nd intercostal space surface parasternal electromyogram (EMGpara)
S116 Parasternal muscle electromyelography (EMGpara) reflects observed changes in dynamic hyperinflation during acute exacerbations of chronic obstructive pulmonary disease (AECOPD)
S117 Respiratory muscle fatigue following exercise in patients with interstitial lung disease
S118 Direct visualisation of collateral ventilation in COPD with hyperpolarised Gas MRI
S119 UK HOT-HMV Trial
S120 Reference values for the incremental shuttle walking test in a healthy population
S121 Mediator profiling of severe asthma phenotypes
S122 Sputum cytokine profiles in asthma and the impact of smoking-a factor analysis
S123 The effect of rhinovirus infection on cough receptors on human sensory nerve and human primary bronchial epithelial cells
S124 RAGE is expressed by human airway smooth muscle cells and expression is increased in asthma
S125 Potential interactions of CRACM ion channels with the calcium activated potassium channel KCa3.1 in human lung mast cells
S126 The cell adhesion receptor CADM1 regulates other adhesion receptors in human mast cells
S127 Anti-protein serological responses to Streptococcus Pneumoniae, in diverse populations
S128 Highly invasive capsular serotypes of Streptococcus pneumoniae bind high levels of Factor H and are resistant to complement and phagocytosis
S129 Neutrophil function and advancing age
S130 HIV-1 infection of macrophages dysregulates pro-inflammatory host responses to Mycobacterium tuberculosis through inhibition of interleukin 10
S131 Human macrophage model of biomass smoke exposure shows impaired ingestion of Streptococcus pneumoniae
S132 Investigating the role of Pellino1, an E3 ubiquitin ligase, in modulating signalling pathways controlling the inflammatory response
S133 The assessment of health related quality of life in interstitial lung disease with the King's brief interstitial lung disease questionnaire (K-BILD)
S134 High prevalence of ischaemic heart disease (IHD) in patients meeting clinico-radiological profile for idiopathic pulmonary fibrosis (IPF)
S135 A retrospective multi-centre study of the effects of allogeneic haematopoietic stem cell transplantation on pulmonary function
S136 The association between cough reflex sensitivity and serum ACE level in patients with sarcoidosis
S137 The natural history of IPF in patients eligible for clinical trials vs patients not eligible
S138 Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole
S139 Cough responses to tussive agents in health and disease
S140 Predictors of 24-h cough frequency in acute cough
S141 TRPA1 expression and characterisation in patients with chronic cough
S142 Investigating patterns in 24 hours of coughing
S143 The sensations provoking cough
S144 Acute cough
S144a Endogenous inhibition of experimentally induced cough in healthy subjects
P1 Clinical and economic benefit of cardiopulmonary exercise testing (CPX) in pulmonary hypertension
P2 In-flight hypoxaemia in patients with pulmonary arterial hypertension (PAH)
P3 Are inflammatory cytokine levels altered by treatment of pulmonary arterial hypertension?
P4 The use of sildenafil to treat pulmonary hypertension associated with sarcoidosis
P5 Pulmonary hypertension in a mouse model with reduced macrophage number (MacLow)
P6 Managing acute pulmonary embolism in the outpatient setting
P7 Are we screening survivors of pulmonary embolism (PE) for chronic thromboembolic pulmonary hypertension (CTEPH)?
P10 Risks of low molecular weight Heparin in suspected pulmonary embolism
P8 Use of D-dimer
P9 Determining the appropriate D-dimer cut-off to exclude pulmonary emboli in an ambulatory care setting using different thresholds based on pre-test probability
P11 Assessment of malignancy in patients with idiopathic pulmonary embolus
P12 Role of Interferon gamma release assay (QuantiFERON–TB Gold In Tube) in blood in the diagnostic work up of active tuberculosis in a high TB prevalence region
P13 Interferon-gamma release assay (IGRA) conversion, reversion and implications for the diagnosis of latent tuberculosis infection using a multimodality approach
P14 Comparison of two interferon-gamma release assays (QuantiFERON-TB Gold In-Tube and T-SPOT.TB) in screening for latent tuberculosis infection (LTBI) among HIV-infected adults attending an inner London HIV clinic
P15 Does an interferon-gamma release assay change practice in patients referred to clinic for possible latent tuberculosis infection?
P16 TB Infection in the UK indigenous white elderly population
P17 Clinical utility of the tuberculosis Interferon Gamma Test (IGT) in a low incidence area
P18 How effective is the recommended staging for latent TB follow-up?
P19 GeneXpert MTB.Rif assay improves the diagnostic yield of EBUS-TBNA in smear-negative intra-thoracic tuberculous lymphadenopathy
P20 Impact of patients' perception of problem driving, symptoms and severity of obstructive sleep apnoea syndrome (OSAS) on outcomes on an advanced office based driving simulator
P21 Does time of day affect outcomes on an advanced office based driving simulator in patients with obstructive sleep apnoea syndrome (OSAS)?
P22 Do obstructive sleep apnoea (OSA) patients with normal Epworth scores comply with Continuous positive airway pressure (CPAP) therapy?
P23 500 consecutive referrals to a DGH sleep service
P24 Prevalence of obstructive sleep apnoea in patients scheduled for bariatric surgery and validation of the STOP-BANG questionnaire as a screening tool
P25 A novel cost-saving approach to the sleep clinic non-attenders with CPAP machines
P26 The UK paediatric sleep videoconferencing circuit
P27 Undergraduate sleep medicine teaching in UK medical schools
P28 The impact of patient information leaflets in sleep clinic
P29 Securing an intercostal chest drain without sutures
P30 What difference does bedside ultrasound guidance make to pleural fluid aspiration and drainage in a district general hospital setting?
P31 Routine analysis of pleural aspirates for AFB in patients with pleural effusion of unknown cause is of limited use
P32 Are junior doctors safe to perform pleural procedures? An audit of junior doctor knowledge and competency of pleural procedures before and after dedicated lecture-based and practical teaching sessions
P33 Thoracic ultrasound training
P34 Are nursing staff sufficiently educated and competent in managing patients with a chest drain?
P35 Primary spontaneous pneumothorax
P36 Respiratory functional status after intrapleural t-PA administration for complicated parapneumonic effusions
P37 Muscle mass in COPD patients receiving angiotensin II receptor blockers and ACE-inhibitors
P38 Is nutritional status neglected in COPD patients admitted to hospital?
P39 Nutritional assessments in COPD
P40 Increased advanced glycation end products in patients with chronic obstructive pulmonary disease (COPD)
P41 Cognitive dysfunction in hospitalised patients prior to discharge following acute exacerbation of COPD
P42 The relationship of home activity levels to psychological co-morbidity in COPD
P43 Assessing the validity of a home activity monitor in patients with COPD
P44 Validation of a pedometer to measure daily physical activities in COPD patients
P45 Co-morbidities in Alpha-1-antitrypsin deficiency
P46 Gender differences in the prevalence of comorbidities in COPD patients
P47 The impact of comorbid ischaemic heart disease on exercise capacity in COPD patients
P48 Should chronic obstructive pulmonary disease be a contra-indication to β blocker prescription in patients with concomitant heart failure?
P49 Intra-subject variation in breath profile of exhaled volatile organic compounds (eVOCs) in chronic obstructive pulmonary disease (COPD)
P50 A summary of strain typing and clustering of TB in London in 2010 and an analysis of the associated risk factors
P51 Tuberculosis outcome following pre-treatment assessment for directly observed or self-administered therapy
P52 Rising paediatric tuberculosis in Greater Manchester
P53 Our experience of avoiding unnecessary bronchoscopies by use of sputum induction for the investigation of suspected tuberculosis
P54 Impact of a rapid access system for early referral of suspected TB cases
P55 TB risk after new immigrant GP registration
P56 Treatment of multidrug resistant tuberculosis
P57 The awareness, perceptions and attitudes among migrants towards TB screening
P58 Indices of TB risk can help stratify recent immigrants registering with a GP for targeted screening
P59 Differing patterns of new immigrant GP registration among ethnic subgroups determine the importance of additional strategies for models of new immigrant screening
P60 Simple measures to improve TB control
P61 Karel Styblo comes to town
P62 Drug induced hypothyroidism in patients receiving treatment for multi-drug resistant tuberculosis
P63 The prevalence of viral hepatitis in patients undergoing anti-tuberculous therapy
P64 The effect of wood smoke on the ability of human macrophages to phagocytose and kill Mycobacterium tuberculosis
P65 Treating tuberculosis in rural South Africa
P66 Inter-observer reliability of ultrasound to measure rectus femoris cross-sectional area in critically ill patients
P67 Clinical predictive value of the medical research council sumscore in critically ill patients
P68 A study to investigate the clinical use and outcomes of EZPAP positive pressure device
P69 A study of the prevalence of hypoxaemia, hypercapnia, hyperoxaemia and acidosis in hospital blood gas specimens (with clinical outcomes)
P70 Does meeting the clinical criteria for the systemic inflammatory response syndrome equate to biochemical inflammation following cardiac surgery?
P71 Relationship between quadriceps rectus femoris cross-sectional area and health related quality of life in patients following critical illness
P72 Relationship between quadriceps rectus femoris anatomical cross-sectional area, physiological cross-sectional area and pennation angle in healthy subjects
P73 Epidemiology and long term outcomes of patients with chronic obstructive pulmonary disease admitted to Scottish intensive care units
P74 Emergency oxygen usage observed by a medical emergency team
P75 Teaching emergency oxygen prescribing to medical students
P76 Long-term effectiveness of a staged assessment for problematic severe asthma
P77 Lung clearance index (LCI) in children with severe, therapy resistant asthma (STRA)
P78 Lung clearance index in children with acute exacerbation of asthma
P79 Do children describe the benefits of inhaled asthma therapy in the same way as adults?
P80 A qualitative exploration of the needs and coping strategies of people with severe asthma
P81 The efficacy of a nurse led, primary care, acute asthma service in reducing short stay hospital admissions
P82 Episodic viral wheeze and multitrigger wheeze
P83 Is a single intramuscular dose of triamcinolone and acute bronchodilator sufficient to determine optimal lung function in children with severe therapy resistant asthma?
P84 BTS National Interstitial Lung Diseases (ILD) Survey 2010–2011
P85 Mortality trends in asbestosis, extrinsic allergic alveolitis and sarcoidosis in England and Wales
P86 The assessment of health related quality of life in sarcoidosis with the King's Sarcoidosis Questionnaire (KSQ)
P87 The needs and experiences of progressive idiopathic fibrotic interstitial lung disease patients, informal caregivers and health professionals
P88 Thalidomide as treatment for IPF associated cough
P89 Ambulatory oxygen assessments in COPD and pulmonary fibrosis
P90 Cyclin-dependent kinases 7 and 9 specifically regulate neutrophil transcription and their inhibition drives apoptosis to promote resolution of inflammation
P91 Are cases of granulomatous common variable immunodeficiency misdiagnosed as sarcoidosis in routine clinical practice?
P92 C reactive protein as a predictive indicator of treatment and disease progression in patients with sarcoidosis
P93 Hospital admission avoidance for people with exacerbations of chronic obstructive pulmonary disease (COPD) through collaborative working between Suffolk COPD services and East of England Ambulance service
P94 Transforming acute care in COPD
P95 Cost effectiveness of overnight face-to-face nurse led COPD service
P96 A comparison between community based models of COPD care
P97 Optimising management and improving outcomes in chronic obstructive pulmonary disease by integrating care
P98 Improving diagnosis and management of COPD
P99 30-Day COPD readmissions relate to disease severity and demographic factors rather than simply organisation and delivery of hospital care
P100 Designing and implementing a COPD discharge care bundle
P101 A survey of emergency oxygen guideline implementation among all 15 UK Ambulance Services in early 2011
P102 A survey of home oxygen provision across London
P103 The practice of prescription of long-term oxygen therapy to patients who continue to smoke
P104 Southampton City
P105 Direct access pulmonary function testing for primary care
P106 Reduction of inappropriate oxygen prescriptions by a home oxygen service
P107 Effectiveness of omalizumab on asthma control and lung function in severe allergic asthma patients in the Czech Republic
P108 Omalizumab for severe allergic asthma
P109 Intravenous aminophylline in the treatment of severe asthma
P110 Fluticasone propionate/formoterol fumarate combination therapy is more efficacious in improving lung function than its individual components in patients with asthma
P111 Fluticasone propionate/formoterol fumarate combination therapy is superior to fluticasone propionate alone in improving asthma control
P112 Fluticasone propionate/formoterol fumarate combination therapy reduces the risk of exacerbations compared with its individual components in patients with asthma
P113 The cost-effectiveness of step down from high dose fluticasone/salmeterol dry powder or suspension formulations in asthma applied to the UK setting
P114 Difficult asthma
P115 Chronic Diesel Exhaust Particle (DEP) exposure differentially alters monocyte differentiation and function in healthy controls compared to COPD
P116 Testing antioxidant and anti-inflammatory therapies in a complex lung tissue model
P117 3D cryo-electron microscopic analysis of the disease mechanism of α1-antitrypsin deficiency
P118 The role of the retinoic acid pathway in human lung regeneration
P119 Changes in airway and systemic IL-18 levels at exacerbation in COPD patients
P120 Comparison of cellular inflammation and TLR expression profiles between healthy and COPD subjects
P121 Differential responses of M1 and M2 monocyte-derived macrophage phenotypes in COPD
P122 No abstract assigned to this number
P123 A retrospective cohort study of the long term effectiveness of smoking cessation counselling
P124 Children unite to stop smoking in cars
P125 Stop smoking as treatment for COPD
P126 Does a personalised and non-clinical explanation of lung health trigger the impulse in smokers to make a quit attempt?
P127 Improving smoking cessation advice through the implementation of a quality improvement intervention
P128 Smoking cessation educational poster campaign
P129 Report of a respiratory health check in a self-selected group of male prisoners in Suffolk
P130 Dynamic hyperinflation is associated with a poor cardiovascular response to exercise in COPD patients
P131 CT emphysema score, dynamic hyperinflation and ventilatory efficiency during exercise in patients with COPD
P132 Comparative study of the Curvilinear Ultrasound Probe (CUP) vs the Linear Ultrasound Probe (LUP) to measure Rectus Femoris Cross Sectional Area (RFcsa)
P133 Lung clearance index is a reproducible and sensitive measure of airways disease in bronchiectasis
P134 Validating structured light plethysmography (SLP) as a non-invasive method of measuring lung function when compared to Spirometry
P135 Maximum inspiratory flow measured directly with an inspiratory flow metre compared with measurements from flow volume loop traces
P136 Comparison between primary care and secondary care spirometry
P137 Interpretation of plethysmography in healthy young children
P138 Evaluation of the need for a comprehensive assessment of lung function pre operatively in the morbidly obese
P139 The use of venturi masks with oxygen concentrators
P140 Uptake and completion of pulmonary rehabilitation
P141 Unwarranted variation in chronic obstructive pulmonary disease care
P142 Pedometer and activity monitor step count reliability compared to visual during walking in patients with chronic respiratory disease
P143 Exploration of patient activity levels following thoracotomy and lung resection
P144 Evaluation of multidisciplinary pulmonary rehabilitation education delivered by either DVD or spoken talk
P145 Effect of pulmonary rehabilitation on waist circumference and waist-hip ratio
P146 Validation of the COPD assessment test (CAT) in pulmonary rehabilitation
P147 Outcomes of pulmonary rehabilitation in severe asthma
P148 The adaptation and evaluation of the living well with COPD programme for pulmonary rehabilitation
P149 Piloting and evaluating post-pulmonary rehabilitation (PR) long-term exercise (LTE) for COPD patients
P150 Use of ambulatory oxygen therapy in pulmonary rehabilitation
P151 Cost of pulmonary rehabilitation is offset by reduction in healthcare utilisation
P152 The National Lung Cancer Audit
P153 Measuring variation in decision making within lung cancer multidisciplinary team (MDT) meetings–a pilot study
P154 The improving lung cancer outcomes project
P155 GP education of the early symptoms of lung cancer
P156 NAEDI lung cancer awareness campaign in London
P157 Follow-up of pulmonary nodules
P158 End of life care for lung cancer; can we identify those in need of support
P159 Rate of chest x-rays (CXR) twelve months prior diagnosis of lung cancer
P160 Turning round lung cancer care in liverpool
P161 Combined 18F-FDG PET/CT as part of a surveillance programme of patients with newly diagnosed pre-invasive endobronchial lesions detects synchronous lung cancers
P162 Comparison of clinical characteristics and outcomes of patients with PET positive vs PET negative solitary pulmonary nodules managed by a Lung MDT
P163 Factors influencing histological confirmation of diagnosis in lung cancer patients
P164 EGFR mutation prevalence in patients with non-small cell lung cancer
P165 Non-tuberculosis mycobacterium infection in Cystic Fibrosis lung disease; effects on bacterial community
P166 Temporal dynamics of polymicrobial communities in the lower respiratory tract of patients with cystic fibrosis
P167 Screening for viral upper respiratory tract infection in pulmonary exacerbations in cystic fibrosis
P168 Eradication of Burkholderia cepacia in CF
P169 Characteristics and survival of patients without cystic fibrosis (CF), isolating mucoid P aeruginosa (mPA) in sputum samples
P170 A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the UK
P171 Impact of heptavalent pneumococcal conjugate vaccine on the incidence of childhood pneumonia seen in hospital in the North East of England
P172 Changes in pneumococcal serotype distribution of paediatric empyema in the age of pneumococcal conjugate vaccines
P173 Comparison of primary pleural drainage strategies in paediatric empyema
P174 Emergence of pneumococcal serotype 19A as a cause of severe complicated pneumonia with empyema in children in England
P175 Mantoux or gamma Interferon (IGRA)—which test is best in children?
P176 Does BCG protect against atopic diseases only for a limited time period?
P177 Evolution of lung function in primary ciliary dyskinesia
P178 The effect of BAL induced inflammation on nasal innate defence – reduction in experimental human pneumococcal carriage
P179 The changing numbers and indications of mediastinoscopy procedures performed following the introduction of endobronchial ultrasound at a UK tertiary centre
P180 Electromagnetic navigation bronchoscopy as a diagnostic method in respiratory medicine
P181 Complications from CT guided lung biopsies and risk factors for pneumothorax
P182 Utility of PET/CT reporting in lung cancer
P183 Comparison of patient satisfaction between endobronchial ultrasound and flexible bronchoscopy performed under conscious sedation
P184 Identifying learning strategies used by respiratory trainees in bronchoscopy
P185 An evaluative study of breath sounds teaching
P186 The reliability of the respiratory physical examination
P187 Does greater physician involvement with interventional procedure coding improve coding outcome?
P188 Impact of ward based chest ultrasound on the radiology department
P189 Evaluation of the role of cardio-pulmonary exercise testing in the diagnosis of unexplained breathlessness
P190 Long-term outcome of bronchial artery embolisation (BAE) for massive haemoptysis
P191 A meta-analysis of adjusted and unadjusted observational studies of sleeve lobectomy vs pneumonectomy for non-small cell lung cancer
P192 Short-term outcome of attempted curative resection for lung cancer in elderly patients
P193 Assessment of performance status in lung cancer
P194 Why do lung cancer patients still die in hospital?
P195 Outcomes in emergency admissions with lung cancer
P196 The cost effectiveness of PET scans in the radical treatment of lung cancer patients in a district general hospital
P197 PET-FDG staging for lung cancer
P198 Is there a role for MRI cranial imaging in patients with non-small cell lung cancer being considered for radical treatment?
P199 A study of symptoms and pathways to treatment in lung cancer patients
P200 Use of hypertonic saline in bronchoprovocation for the diagnosis of bronchial asthma
P201 No abstract assigned to this number
P202 Impact study of 243 indirect bronchial provocation tests with mannitol in the diagnosis and management of asthma
P203 Correlation of Nijmegen score and hospital anxiety/depression (HAD) score in dysfunctional breathlessness
P204 The Burden of repeated asthma admissions and associations with psychiatric comorbidity
P205 Managing the challenges of recruitment of patients with asthma to randomised controlled trials
P206 Psychological comorbidity in vocal cord dysfunction
P207 Does the Nijmegen correlate to the D12 when used as an outcome measure in patients with breathing pattern dysfunction
P208 Obesity augments circulating neutrophil levels in asthma
P209 Risk factors for respiratory exacerbations in the BOLD study
P210 Which symptoms prompt patients with an exacerbation of COPD to persevere, self-treat or seek care? A comparison with health professionals
P211 Exacerbation frequency and maintenance treatment of COPD in UK clinical practice
P212 The DECAF score
P213 Longitudinal changes in the rate and mean age of incidence and prevalence of COPD in the UK, 2000–2009
P214 Acute exacerbations of COPD
P215 The effect of Oxygen prescription at hospital discharge on re-admission rates in Chronic Obstructive Pulmonary Disease (COPD)
P216 Recruiting COPD inpatients to clinical research
P217 Factors affecting patient satisfaction in a COPD research cohort
P218 Recording of COPD mortality must improve if it is to be a robust outcome measure
P219 Ten year mortality in a primary care COPD cohort
P220 Transfer factor and arterial oxygen partial pressure are predictors of survival in hospital outpatients with COPD
P221 Advance care planning in chronic obstructive pulmonary disease
P222 Multi-Disciplinary Team Attitudes Towards End-of-Life Care in Severe COPD
P223 End of life discussion in pulmonary rehabilitation
P223a Increasing the quality of COPD case finding, diagnosis and management through a primary care financial incentive scheme in inner London
P224 The impact of implementing a collaborative antimicrobial ward round model within the Respiratory Directorate of a large university teaching hospital
P225 The post pandemic influenza experience in a busy district general hospital
P226 Managing suspected pulmonary embolism in an ambulatory setting
P227 Development of a preliminary questionnaire for the identification of vocal cord dysfunction
P228 An audit of the effectiveness of competency based spirometry training
P229 Factors affecting inhaler choice and adherence in urban Liverpool
P230 Do we need a “two week rule” referral pathway for lung cancer?
P231 “Safety-net” for abnormal chest radiographs with a low index of suspicion for malignancy
P232 Short-term outcomes in heart failure patients with chronic obstructive pulmonary disease in the community
P233 Judicious use of oximetry can help deliver cost effective sleep service
P234 The importance of appropriate reference equations for spirometry
P235 A UK registry study of prophylactic antibiotic use for Staphylococcus aureus in children with cystic fibrosis
P236 Cystic Fibrosis deaths in USA and UK
P237 Does desaturation on exercise predict nocturnal hypoxia in children with cystic fibrosis?
P238 Prescription issue data as a measure of adherence with nebulised therapy in an adult cystic fibrosis centre
P239 Radiation exposure in adults with cystic fibrosis
P240 Pneumothorax management in cystic fibrosis patients
P241 Accuchek (TM) measurement of blood glucose correlates with true lab glucose measurement in children screened for cystic fibrosis related diabetes
P242 Bone density and testosterone levels in male cystic fibrosis patients
P243 Anxiety and depression in adolescents and adults with cystic fibrosis
P244 Risk stratification of flu in post-pandemic winter 2010
P245 Can clinical, radiological or laboratory parameters differentiate H1N1 associated pneumonia from community acquired pneumonia?
P246 Airway and systemic inflammation in stable and exacerbated bronchiectasis
P247 The respiratory phenotype of the BBS4 null mouse lung
P248 Associations of depression, fatigue and quality of life in adult non-CF bronchiectasis
P249 Assessment of health related quality of life (HRQoL) in non-cystic fibrosis bronchiectasis using a new disease-specific tool for measuring HRQoL
P250 Mycoplasma pneumonia. Presenting features and diagnosis in our district general hospital in 2010
P251 Junior doctors' interpretation of CXRs is more consistent than consultants in the context of possible pneumonia
P252 Once-daily NVA237 improves symptoms, and reduces COPD exacerbations and associated hospitalisations
P253 NVA237 once daily offers rapid and clinically meaningful bronchodilation in COPD patients that is maintained for 24 h
P254 NVA237 once daily improves exercise endurance in patients with COPD from the first dose
P256 Aclidinium bromide
P257 Effects of extra-fine inhaled and oral corticosteroids on alveolar nitric oxide in COPD
P258 Role of 7-day and 14-day courses of oral prednisolone treatment in acute exacerbation of COPD
P259 Effects of metformin on clinical outcome in patients hospitalised for COPD exacerbations
P260 Oral nutritional supplements in chronic obstructive pulmonary disease (COPD)
P261 Does the provision of a rescue pack keep patients with chronic obstructive pulmonary disease (COPD) at home?
P262 Oramorph for breathlessness
P263 Cannabis use, respiratory symptoms and lung function, in a North Edinburgh primary care population
P264 The prevalence of β-blocker prescription in COPD patients
P265 A randomised control trial to investigate the effectiveness of PLB in the clinical setting
P266 Late ventilation is associated with high in-hospital mortality in patients hospitalised with acute exacerbations of COPD
P267 Association of the length of non-invasive ventilation (NIV) with arterial bicarbonate level in COPD patients with acute hypercapnic respiratory failure (AHRF)
P268 Can we improve “door-to-mask” times for patients with chronic obstructive pulmonary disease (COPD) requiring non-invasive ventilation (NIV)?
P269 Feasibility and acceptability of non-invasive ventilation (NIV) as an aid to exercise in patients admitted with acute exacerbation of chronic respiratory disease
P270 Motor neurone disease (MND); a survey of deaths in the era of non-invasive ventilation
P271 Impact of structured referral and follow-up pathways on access to ventilatory support for people with motor neurone disease (MND)
P272 A 7 year retrospective evaluation of initiation of long term non-invasive ventilatory support for motor neurone disease
P273 Outcome after prolonged invasive mechanical ventilation in myotonic dystrophy
P274 Seasonal variation in initiation and discontinuation of domiciliary non-invasive ventilation
P275 An afferent reservoir enables the Nippy 1 to deliver any gas
P276 The value of vital capacity and daytime pulse oximetry to predict hypercapnia in obese patients